An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Animal models are used to better understand the various mechanisms involved in the pathogenesis of diseases and explore potential pathways that will aid in discovering therapeutic targets. 3-Nitropropionic Acid (3-NPA) is a neurotoxin used to induce Huntington's disease (HD)-like symptoms in experimental animals. The 3-NPA is a fungus toxin that impairs the complex II (succinate dehydrogenase) activity of the mitochondria and reduces ATP synthesis, leading to excessive production of free radicals resulting in the degeneration of GABAergic medium spiny neurons (MSNs) in the striatum. This is characterized by motor impairments a key clinical manifestation of HD. 3-NPA has the potential to alter several cellular processes, including mitochondrial functions, oxidative stress, apoptosis, and neuroinflammation mimicking HD-like pathogenic conditions in animals. This review strives to provide a new insight towards the 3-NPA induced molecular dysfunctioning in developing an animal model of HD. Moreover, we summarise several preclinical studies that support the use of the 3-NPA-induced models for drug discovery and development in HD. This review is a collection of various articles that were published from 1977 to 2022 on Pubmed (1639), Web of Science (2139), and Scopus (2681), which are related to the 3-NPA induced animal model. Graphical Abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Neurochemical research - 48(2023), 6 vom: 04. Feb., Seite 1631-1647 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Upadhayay, Shubham [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
3-Nitropropionic acid (3-NPA) |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11064-023-03868-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2134580666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2134580666 | ||
| 003 | DE-627 | ||
| 005 | 20230510162554.0 | ||
| 007 | tu | ||
| 008 | 230510s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11064-023-03868-1 |2 doi | |
| 035 | |a (DE-627)OLC2134580666 | ||
| 035 | |a (DE-He213)s11064-023-03868-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Upadhayay, Shubham |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Animal models are used to better understand the various mechanisms involved in the pathogenesis of diseases and explore potential pathways that will aid in discovering therapeutic targets. 3-Nitropropionic Acid (3-NPA) is a neurotoxin used to induce Huntington's disease (HD)-like symptoms in experimental animals. The 3-NPA is a fungus toxin that impairs the complex II (succinate dehydrogenase) activity of the mitochondria and reduces ATP synthesis, leading to excessive production of free radicals resulting in the degeneration of GABAergic medium spiny neurons (MSNs) in the striatum. This is characterized by motor impairments a key clinical manifestation of HD. 3-NPA has the potential to alter several cellular processes, including mitochondrial functions, oxidative stress, apoptosis, and neuroinflammation mimicking HD-like pathogenic conditions in animals. This review strives to provide a new insight towards the 3-NPA induced molecular dysfunctioning in developing an animal model of HD. Moreover, we summarise several preclinical studies that support the use of the 3-NPA-induced models for drug discovery and development in HD. This review is a collection of various articles that were published from 1977 to 2022 on Pubmed (1639), Web of Science (2139), and Scopus (2681), which are related to the 3-NPA induced animal model. Graphical Abstract | ||
| 650 | 4 | |a 3-Nitropropionic acid (3-NPA) | |
| 650 | 4 | |a Mitochondrial Dysfunction; Excitotoxicity | |
| 650 | 4 | |a Animal Model | |
| 650 | 4 | |a Neurodegeneration | |
| 650 | 4 | |a Huntington’s Disorder | |
| 700 | 1 | |a Yedke, Narhari Gangaram |4 aut | |
| 700 | 1 | |a Rahi, Vikrant |4 aut | |
| 700 | 1 | |a Singh, Surbhi |4 aut | |
| 700 | 1 | |a Kumar, Sachin |4 aut | |
| 700 | 1 | |a Arora, Anchal |4 aut | |
| 700 | 1 | |a Chandolia, Priyanka |4 aut | |
| 700 | 1 | |a Kaur, Prabhsharan |4 aut | |
| 700 | 1 | |a Kumar, Mandeep |4 aut | |
| 700 | 1 | |a Koshal, Prashant |4 aut | |
| 700 | 1 | |a Jamwal, Sumit |4 aut | |
| 700 | 1 | |a Kumar, Puneet |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurochemical research |d Springer US, 1976 |g 48(2023), 6 vom: 04. Feb., Seite 1631-1647 |w (DE-627)129455679 |w (DE-600)199335-5 |w (DE-576)01481904X |x 0364-3190 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g number:6 |g day:04 |g month:02 |g pages:1631-1647 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11064-023-03868-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |e 6 |b 04 |c 02 |h 1631-1647 | ||